Engineering Dendritic Cells to Enhance Cancer Immunotherapy
Open Access
- 1 May 2011
- journal article
- review article
- Published by Elsevier in Molecular Therapy
- Vol. 19 (5) , 841-853
- https://doi.org/10.1038/mt.2011.57
Abstract
No abstract availableKeywords
This publication has 133 references indexed in Scilit:
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccinationProceedings of the National Academy of Sciences, 2010
- Inhibitory RNA Molecules in Immunotherapy for CancerPublished by Springer Nature ,2010
- Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and functionTrends in Immunology, 2009
- Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor ImmunityMolecular Therapy, 2009
- Vesicular Stomatitis Virus M Protein Mutant Stimulates Maturation of Toll-Like Receptor 7 (TLR7)-Positive Dendritic Cells through TLR-Dependent and -Independent MechanismsJournal of Virology, 2009
- In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccinationProceedings of the National Academy of Sciences, 2008
- Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic MelanomaJournal of Immunotherapy, 2008
- A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell–mediated suppressionNature Medicine, 2008
- Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15Immunity, 2007